USPTO published patent application US20260092072A1 covering novel aldose reductase inhibitor compounds and pharmaceutical compositions for multiple therapeutic indications. The application discloses compounds for promoting healthy skin aging, treating cardiovascular disorders (atherosclerosis, cardiomyopathy, coronary artery disease), renal disorders (diabetic nephropathy), diabetes complications (neuropathy, retinopathy, cardiomyopathy), cancer (angiogenesis disorders), and other conditions including stroke, peripheral vascular disease, asthma, and PMM2-CDG. The filing identifies Andrew WASMUTH as inventor with CPC classifications C07D 495/04 (heterocyclic compounds) and C07H 15/26 (sugars derivatives).

This is a published patent application, not an issued patent or regulatory guidance. No compliance deadlines, penalties, or required actions apply to third parties. Pharmaceutical companies and researchers in aldose reductase inhibition may wish to review for freedom-to-operate considerations or potential licensing opportunities. The application remains pending examination and may be amended during prosecution.